Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4315266 | 0.86 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| Hydrochloric Acid SCHEMBL10512940 | 0.85 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL715601 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL10511175 | 0.84 | SLC6A2 (0.39) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| Hydrochloric Acid SCHEMBL3938043 | 0.82 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL10510000 | 0.82 | HTR1D (0.40) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL947340 | 0.82 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| Hydrochloric Acid SCHEMBL10513272 | 0.81 | SLC6A2 (0.37) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| Hydrochloric Acid SCHEMBL10511305 | 0.81 | HTR1D (0.40) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 | |
| SCHEMBL7466842 | 0.80 | KDM4E (0.42) | SLC6A2SLC6A3SLC6A4HTR2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989446-B2 | 4-amino 5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-01-13 | — | — | US | disclosed |
| US-7834002-B2 | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1740574-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105778-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | disclosed |
| EP-0858452-B1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-03-13 | — | — | EP | disclosed |
| US-6140330-A | USEFUL AS PROTEIN KINASE INHIBITOR; FOR TREATMENT OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, MULTIPLE SCLEROSIS, PSORIASIS, ETC., VARIOUS ALLERGIC DISEASES SUCH AS CROHN'S DISEASE, ASTHMA | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0858452-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998004536-A1 | THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1998-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | SLC6A2 1291/4885SLC6A3 2302/4885SLC6A4 853/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | SLC6A2 1291/4885SLC6A3 2302/4885SLC6A4 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.